Dr. Lara on Epacadostat Plus Pembrolizumab in RCC

Primo N. Lara, MD
Published: Friday, Jun 23, 2017



Primo N. Lara, MD, associate director for translational research, UC Davis Comprehensive Cancer Center, discusses epacadostat plus pembrolizumab (Keytruda) in patients with metastatic renal cell carcinoma (RCC).

The phase Ib/II trial showed encouraging response rates and safety signals for this combination, particularly with patients who had minimally pretreated disease.

The confirmed response rate was 47%. In this study, only 17% of patients experienced grade 3 or higher toxicity, which is what is expected with single agent checkpoint inhibitor therapy.
 


Primo N. Lara, MD, associate director for translational research, UC Davis Comprehensive Cancer Center, discusses epacadostat plus pembrolizumab (Keytruda) in patients with metastatic renal cell carcinoma (RCC).

The phase Ib/II trial showed encouraging response rates and safety signals for this combination, particularly with patients who had minimally pretreated disease.

The confirmed response rate was 47%. In this study, only 17% of patients experienced grade 3 or higher toxicity, which is what is expected with single agent checkpoint inhibitor therapy.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: The Next Generation in Renal Cell Carcinoma Treatment: An Oncology Nursing Essentials WorkshopJul 31, 20181.5
Publication Bottom Border
Border Publication
x